The effectiveness of the S-1 clears the way for the company to begin trading on Nasdaq. Watch for the pricing announcement and first day of trading, which typically follow within 1-2 days of effectiveness for IPOs. The direct listing structure means no new capital is raised, but existing shareholders can sell.
Price Chart
Executive Summary
The SEC declared effective a registration statement (File No. 333-299027) for Lakewood-Amedex Biotherapeutics Inc. on September 24, 2026. This follows a recent S-1 filed on September 18, 2026, and a prior S-1 from May 2026, indicating the company is progressing toward an IPO or direct listing on Nasdaq.
Key Facts
- Effectiveness date: September 24, 2026
- SEC File Number: 333-299027
- Registration statement type: S-1 (IPO/direct listing)
- Prior S-1 filed September 18, 2026 (6 days before effectiveness)
- Prior S-1/A filed April 6, 2026 (amendment for direct listing)
- Company is a clinical-stage biopharmaceutical company (SIC 2834)
- Common stock trades on Nasdaq Capital Market under symbol LABT
Financial Impact
Offering size not disclosed in the EFFECT filing; prior S-1/A from April 2026 registered up to 4,689,177 shares for resale in a direct listing; more recent S-1 from September 2026 may have different terms.
Risk Factors
- No new capital raised in a direct listing — company remains dependent on existing cash runway
- Potential selling pressure from registered stockholders (up to 4.7M shares from prior filing)
- Clinical-stage biotech with no approved products and history of operating losses
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003056 |
| Document: 9999999995-26-003056-index.html | 9999999995-26-003056 |
| Document: 9999999995-26-003056.txt | 9999999995-26-003056 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | EFFECT | $1.67 $0.3100 | ▼ −81.44% | ▼ −79.96% | $0.2644 (−84.17%) |
Sep 18, 2026 5w ago | S-1 | $2.05 $0.5834 | ▲ +71.54% | ▲ +70.63% | $0.2644 (+87.10%) |
Jun 17, 2026 18w ago | 8-K | $0.6022 $0.1890 | ▼ −68.62% | ▼ −68.93% | $0.2644 (−56.09%) |
May 14, 2026 23w ago | EFFECT | $19.60 $7.70 | ▲ +60.71% | ▲ +59.86% | $0.2644 (+98.65%) |
May 6, 2026 24w ago | 3 | $33.00 $6.70 | ▼ −79.70% | ▼ −80.51% | $0.2644 (−99.20%) |
Apr 20, 2026 27w ago | EFFECT | — | awaiting T+20 | — | — |
Apr 1, 2026 29w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 11, 2026 32w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers